Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company focused on mRNA medicines, with multiple approved vaccines and a broad clinical pipeline. The MRNA news page on Stock Titan aggregates company announcements, investor updates and regulatory developments so readers can follow how Moderna’s strategy and pipeline progress translate into real-world events.
Investors and observers can use this feed to track commercial updates on products such as Spikevax, mRESVIA and mNEXSPIKE, along with developments in late-stage respiratory programs like the seasonal influenza vaccine mRNA-1010, the flu/COVID combination vaccine mRNA-1083 and the Norovirus vaccine candidate mRNA-1403. News items often cover regulatory submissions and opinions from agencies including the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada and others.
The page also surfaces pipeline and clinical trial news in oncology and rare diseases, including updates on mRNA-4157 (intismeran autogene), mRNA-4359, mRNA-3927 for propionic acidemia and mRNA-3705 for methylmalonic acidemia. Announcements related to partnerships, such as CEPI’s funding commitment for the H5 pandemic influenza vaccine candidate mRNA-1018, appear here as well.
In addition, the MRNA news feed includes financial results, guidance and capital structure updates, such as quarterly earnings releases, multi-year financial frameworks and information on facilities like the $1.5 billion credit agreement. Corporate items, including participation in healthcare conferences, Analyst Day presentations and shareholder meeting outcomes, are also reflected.
By reviewing this consolidated news stream, readers can see how Moderna’s respiratory vaccine franchise, oncology and rare disease programs, manufacturing expansion and financing decisions evolve over time, all based on the company’s own disclosures and related announcements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Moderna, Inc. (Nasdaq:MRNA) will conduct a live conference call and webcast on May 4, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 financial results and provide a corporate update.
The call will be accessible via the Moderna Investors website, with an archived version available two hours post-call for one year.
Founded over a decade ago, Moderna has evolved from a research-stage company into a leader in mRNA therapeutics and vaccines, successfully producing COVID-19 vaccines and developing a wide range of therapeutics. The company is recognized for its innovative mRNA technology and robust manufacturing capabilities, maintaining collaborative relationships to advance scientific and therapeutic breakthroughs.
Moderna (Nasdaq:MRNA) has entered into a partnership with IBM (NYSE:IBM) to leverage quantum computing and artificial intelligence for advancing mRNA medicine development. This collaboration includes investments in generative AI to enhance product design.
Moderna aims to build a workforce skilled in quantum technologies and will participate in IBM's Quantum Accelerator program. The goal is to apply quantum computing to complex scientific challenges, enhancing mRNA therapeutics.
Additionally, the companies will utilize the MoLFormer AI model to optimize lipid nanoparticles and mRNA, targeting improved safety and performance in new mRNA medicines. This investment underscores Moderna's commitment to pioneering technology in biotechnology.
Moderna and Merck announced positive results from the Phase 2b KEYNOTE-942 trial involving mRNA-4157 (V940) in combination with KEYTRUDA for treating high-risk stage III/IV melanoma. The combination therapy reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone. The trial included 157 patients with a median follow-up of 23-24 months. In the combination group, 83.4% of patients were recurrence-free at 12 months, compared to 77.1% in the control group. The U.S. FDA granted Breakthrough Therapy Designation for this therapy. A Phase 3 study will start in 2023.
Moderna, Inc. (NASDAQ: MRNA) has made significant advancements in its clinical pipeline, including the dosing of the first participant in the Phase 3 trial for its next-generation COVID-19 vaccine, mRNA-1283. The company is also preparing to file for approval of another vaccine candidate, mRNA-1345, targeting RSV, within this quarter. However, the first influenza vaccine candidate, mRNA-1010, faced challenges as it did not achieve sufficient cases in an interim efficacy analysis, leading to continued follow-up recommendations from the independent DSMB. Positive preliminary results indicate strong immunogenicity against certain influenza strains. Moderna has introduced new vaccine candidates for Lyme disease and norovirus. The company established a financial framework projecting sales in its respiratory franchise to reach between $8 billion to $15 billion by 2027.